1. Home
  2. TSLX vs PGEN Comparison

TSLX vs PGEN Comparison

Compare TSLX & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sixth Street Specialty Lending Inc.

TSLX

Sixth Street Specialty Lending Inc.

HOLD

Current Price

$17.78

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$4.09

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSLX
PGEN
Founded
2010
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.4B
IPO Year
2011
2013

Fundamental Metrics

Financial Performance
Metric
TSLX
PGEN
Price
$17.78
$4.09
Analyst Decision
Buy
Buy
Analyst Count
9
5
Target Price
$21.61
$8.33
AVG Volume (30 Days)
765.5K
2.9M
Earning Date
05-05-2026
05-13-2026
Dividend Yield
10.82%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$230,981,000.00
Revenue This Year
N/A
$1,115.92
Revenue Next Year
$1.20
$81.04
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$16.99
$1.28
52 Week High
$25.17
$5.47

Technical Indicators

Market Signals
Indicator
TSLX
PGEN
Relative Strength Index (RSI) 43.18 48.32
Support Level $17.25 $3.97
Resistance Level $18.65 $4.40
Average True Range (ATR) 0.52 0.24
MACD -0.13 -0.00
Stochastic Oscillator 20.31 15.26

Price Performance

Historical Comparison
TSLX
PGEN

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

About PGEN Precigen Inc.

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Share on Social Networks: